Medicine:OSI-7904L
From HandWiki
Revision as of 03:53, 9 March 2021 by imported>Rtexter1 (fix)
OSI-7904L is a novel noncompetitive liposomal thymidylate synthase inhibitor. OSI-7904 is a benzoquinazoline folate analog with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication.[1] OSI-7904L is a liposome-encapsulated formulation of OSI-7904. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904.[1]
Its effect on solid tumours is currently under evaluation.[2][3][4]
References
- ↑ 1.0 1.1 "NCI Drug Dictionary: OSI-7904L". National Cancer Institute. http://www.cancer.gov/drugdictionary?cdrid=352016.
- ↑ "Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors". Clin. Cancer Res. 14 (23): 7947–55. December 2008. doi:10.1158/1078-0432.CCR-08-0864. PMID 19047127. http://clincancerres.aacrjournals.org/content/clincanres/14/23/7947.full.pdf.
- ↑ "Phase I study of liposomal thymidylate synthase inhibitor (TSI) OSI-7904L in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: 2003 (abstr 561)". http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101198.
- ↑ "A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology April 2008, Volume 61, Issue 4, pp 579-585". Cancer Chemotherapy and Pharmacology 61 (4): 579–585. doi:10.1007/s00280-007-0509-5. https://link.springer.com/article/10.1007%2Fs00280-007-0509-5?LI=true.
 |
